Supplements
green tea decreases cancer risk
In plain terms: Does green tea prevent cancer?
Part of: 🧪 Green tea
Not broadly. The Cochrane review of this question - one review in two editions, 2009 and its 2020 update - found no convincing overall cancer-prevention effect. Some individual (mostly observational) studies link green tea to lower risk of specific cancers - stomach, oral, breast, esophageal - but that evidence is weaker and inconsistent. Not a reliable cancer preventive.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
The broad 'green tea prevents cancer' claim is NOT supported by the strongest evidence. The Cochrane review judged it insufficient/inconsistent; the largest dose-response meta-analysis across five cancers found no overall benefit (and black tea was a breast-cancer risk factor); breast and colorectal analyses are null. An umbrella review found 'convincing' evidence only for oral cancer.
The evidence (17)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Kim TL et al. 2020 · Adv Nutr | observational | mixed | moderate | Umbrella review 64 observational studies: only ORAL cancer met 'convincing' criteria (OR 0.62); most other sites weak/non-significant. |
| He JJ et al 2025 · study_type: animal | animal | supports | moderate | Systematic review/meta-analysis of 20 preclinical studies (mouse/rat models) of green tea extract/EGCG in breast, ovarian, uterine cancer; pooled tumor volume reduced (Hedge's g=-2.332) and tumor weight reduced (Hedge's g=-2.105), EGCG null |
| Altinoz HB et al 2026 · study_type: observational | observational | mixed | low | Narrative review of green tea catechins and prostate cancer; preclinical/in-vitro mechanisms promising but abstract states clinical evidence remains limited due to few, small human trials. |
| Yu F et al. 2014 · BMC Cancer | meta-analysis | contradicts | high | Dose-response meta 41 cohorts (3M participants, 5 cancers): NO overall inverse association; black tea was a breast-cancer risk factor (RR 1.18). |
| Zhao L et al. 2021 · Nutrition | observational | supports | moderate | Dose-response meta: inverse green tea - esophageal cancer. |
| Funabashi O et al 2026 · study_type: observational | observational | supports | moderate | JACC prospective cohort of 41,999 Japanese adults; green tea consumption inversely associated with liver cancer incidence, HR 0.61 (95% CI 0.40-0.95) for ≥7 cups/day vs <1 cup/day (p-trend=0.029). |
| Zhang Y et al. 2025 · Am J Chin Med | observational | supports | high | Meta 43 studies: green tea RR 0.91 overall; EGCG RR 0.72; prostate 0.43, oral 0.44. |
| Wang Y et al. 2021 · Public Health Nutr | observational | tested-null | moderate | Network meta (45 studies, 3.3M): tea/coffee NOT associated with lower overall breast cancer; only a weak ER-negative signal at >=5 cups/d. |
| Najaf Najafi M et al. 2018 · Phytother Res | observational | supports | moderate | Meta 14 studies: green tea - breast cancer OR 0.81. |
| Zheng S et al 2025 · study_type: observational | observational | supports | moderate | UK Biobank prospective cohort, 276,209 participants, 3,821 incident lung cancers; tea consumption associated with lower lung cancer risk (e.g. HR 0.67, 95% CI 0.60-0.76 for 2-3 cups/day vs non-drinkers), non-linear dose-response. |
| Gianfredi V et al. 2018 · Nutrients | observational | supports | moderate | Meta 13 studies: green tea inversely associated with breast cancer OR 0.85. |
| Boehm K et al. 2009 · Cochrane Database Syst Rev | observational | contradicts | high | Cochrane review (RCTs + observational): evidence insufficient/inconsistent; no established site-specific cancer-prevention effect. |
| Ishikawa H et al 2026 · study_type: RCT | RCT | mixed | low | Double-blind RCT (J-FAPP Study I), 80 FAP patients randomized to green tea extract (1.5g/day, 2 years) vs placebo; colorectal polyp enlargement risk ratio 0.43 (95% CI 0.12-1.49, p=0.16). |
| Liu Y et al. 2023 · Nutr Hosp | observational | supports | low | Network meta 14 RCTs (73,365 men): ranked green tea catechins highest for reducing prostate cancer risk, but authors say more quality evidence needed. |
| Huang Y et al. 2017 · Public Health Nutr | observational | supports | moderate | Dose-response meta: inverse green tea - gastric cancer. |
| Myung SK et al. 2009 · Int J Cancer | observational | tested-null | moderate | Meta: stomach cancer case-control OR 0.73 (protective) but cohort RR 1.04 (null) - the classic design split. |
| Filippini T et al. 2020 · Cochrane Database Syst Rev | observational | contradicts | high | Cochrane (updated): no convincing evidence green tea reduces cancer incidence; low-certainty subgroup signals. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.